Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexia Tiberi has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Antonino Cattaneo

    Laboratorio di Biologia BIO@SNS, Scuola Normale Superiore, Pisa, Italy

    3 shared publications
  • Simona Capsoni

    Bio@SNS Laboratory, Scuola Normale Superiore, Pisa, Italy

    3 shared publications
  • A. Ardura-Fabregat

    Faculty of Medicine, Institute of Neuropathology, University of Freiburg, Freiburg, Germany

    1 shared publication
  • A. Paulus

    Experimental Neuroinflammation Laboratory, Department of Experimental Medical Sciences, Biomedical Centrum (BMC), Lund University, Lund, Sweden

    1 shared publication
  • A. Vautheny

    Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de la Recherche Fondamentale (DRF), Institut de biologie François Jacob, MIRCen, 92260, Fontenay-aux-Roses, France

    1 shared publication
  • A. Webers

    Department of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Sigmund-Freud Str. 25, 53127, Bonn, Germany

    1 shared publication

Latest Publications

  • Open Access

    Microglia drive synaptic and functional connectivity deficits in the Ts65Dn mouse model of Down syndrome by affecting inhibition

    by Alexia Tiberi, Elena Montagni, Giulia Borgonovo, Eléa Coulomb, Laura Restani, Anna Letizia Allegra Mascaro, Simona Capsoni, Antonino Cattaneo

    Microglia, the resident immune cells of the brain, play a crucial role in sculpting neuronal circuits during development, and their dysfunction is increasi


  • Open Access

    Human TrkAR649W mutation impairs nociception, sweating and cognitive abilities: a mouse model of HSAN IV

    by Paola Pacifico, Giovanna Testa, Rosy Amodeo, Marco Mainardi, Alexia Tiberi, Domenica Convertino, Juan Carlos Arevalo, Laura Marchetti, Mario Costa, Antonino Cattaneo, et al.

    A functional nerve growth factor NGF–Tropomyosin Receptor kinase A (TrkA) system is an essential requisite for the generation and maintenance of long-lasting thermal and mechanical hyperalgesia in adult mammals. Indeed, mutations in the gene encoding for TrkA are responsible for a rare condition, named Hereditary Sensory and Autonomic Neuropathy type IV (HSAN IV), characterized by the loss of response to noxious stimuli, anhidrosis and cognitive impairment. However, to date, there is no available mouse model to properly understand how the NGF–TrkA system can lead to pathological phenotypes that are distinctive of HSAN IV. Here, we report the generation of a knock-in mouse line carrying the HSAN IV TrkAR649W mutation. First, by in vitro biochemical and biophysical analyses, we show that the pathological R649W mutation leads to kinase-inactive TrkA also affecting its membrane dynamics and trafficking. In agreement with the HSAN IV human phenotype, TrkAR649W/m mice display a lower response to thermal and chemical noxious stimuli, correlating with reduced skin innervation, in addition to decreased sweating in comparison to TrkAh/m controls. Moreover, the R649W mutation decreases anxiety-like behavior and compromises cognitive abilities, by impairing spatial-working and social memory. Our results further uncover unexplored roles of TrkA in thermoregulation and sociability. In addition to accurately recapitulating the clinical manifestations of HSAN IV patients, our findings contribute to clarifying the involvement of the NGF–TrkA system in pain sensation.


  • Open Access

    A Microglial Function for the Nerve Growth Factor: Predictions of the Unpredictable

    by Alexia Tiberi, Simona Capsoni, Antonino Cattaneo

    Microglia are the only immune cell population present in the brain parenchyma. Their vantage position in the central nervous system (CNS) enables these myeloid cells to perform the most disparate of tasks: from the classical immune functions of fighting infections and surveilling the extracellular space for pathogens and damage, to sculpting the neuronal circuitry by pruning unnecessary synapses and assisting neurons in spine formation, aiding in the maintenance of brain homeostasis. The neurotrophin field has always been dominated by the neurocentric view that the primary target of these molecules must be neurons: this holds true even for the Nerve Growth Factor (NGF), which owes its popularity in the neuroscience community to its trophic and tropic activity towards sensory and sympathetic neurons in the peripheral nervous system, and cholinergic neurons in the CNS. The increasing evidence that microglia are an integral part of neuronal computation calls for a closer look as to whether these glial cells are capable of responding directly to NGF. In this review, we will first outline evidence in support of a role for NGF as a molecule mediating neuroimmune communication. Then, we will illustrate some of those non-immune features that have made microglial cells one of the hottest topics of this last decade. In conclusion, we will discuss evidence in support of a microglial function for NGF.


  • Regulation of BACE1 expression after injury is linked to the p75 neurotrophin receptor

    by Khalil Saadipour, Alexia Tiberi, Sylvia Lombardo, Elena Grajales, Laura Montroull, Noralyn B. Mañucat-Tan, John LaFrancois, Michael Cammer, Paul M. Mathews, Helen E. Scharfman, et al.


  • Open Access

    NGF steers microglia toward a neuroprotective phenotype

    by Caterina Rizzi, Alexia Tiberi, Michela Giustizieri, Maria Cristina Marrone, Francesco Gobbo, Nicola Maria Carucci, Giovanni Meli, Ivan Arisi, Mara D'ONofrio, Silvia Marinelli, et al.

    Microglia are the sentinels of the brain but a clear understanding of the factors that modulate their activation in physiological and pathological conditions is still lacking. Here we demonstrate that Nerve Growth Factor (NGF) acts on microglia by steering them toward a neuroprotective and anti‐inflammatory phenotype. We show that microglial cells express functional NGF receptors in vitro and ex vivo. Our transcriptomic analysis reveals how, in primary microglia, NGF treatment leads to a modulation of motility, phagocytosis and degradation pathways. At the functional level, NGF induces an increase in membrane dynamics and macropinocytosis and, in vivo, it activates an outward rectifying current that appears to modulate glutamatergic neurotransmission in nearby neurons. Since microglia are supposed to be a major player in Aβ peptide clearance in the brain, we tested the effects of NGF on its phagocytosis. NGF was shown to promote TrkA‐mediated engulfment of Aβ by microglia, and to enhance its degradation. Additionally, the proinflammatory activation induced by Aβ treatment is counteracted by the concomitant administration of NGF. Moreover, by acting specifically on microglia, NGF protects neurons from the Aβ‐induced loss of dendritic spines and inhibition of long term potentiation. Finally, in an ex‐vivo setup of acute brain slices, we observed a similar increase in Aβ engulfment by microglial cells under the influence of NGF. Our work substantiates a role for NGF in the regulation of microglial homeostatic activities and points toward this neurotrophin as a neuroprotective agent in Aβ accumulation pathologies, via its anti‐inflammatory activity on microglia.


  • Open Access

    Targeting Neuroinflammation to Treat Alzheimer’s Disease

    by A. Ardura-Fabregat, E. W. G. M. Boddeke, A. Boza-Serrano, S. Brioschi, S. Castro-Gomez, K. Ceyzériat, C. Dansokho, T. Dierkes, G. Gelders, Michael T. Heneka, et al.

    Over the past few decades, research on Alzheimer’s disease (AD) has focused on pathomechanisms linked to two of the major pathological hallmarks of extracellular deposition of beta-amyloid peptides and intra-neuronal formation of neurofibrils. Recently, a third disease component, the neuroinflammatory reaction mediated by cerebral innate immune cells, has entered the spotlight, prompted by findings from genetic, pre-clinical, and clinical studies. Various proteins that arise during neurodegeneration, including beta-amyloid, tau, heat shock proteins, and chromogranin, among others, act as danger-associated molecular patterns, that—upon engagement of pattern recognition receptors—induce inflammatory signaling pathways and ultimately lead to the production and release of immune mediators. These may have beneficial effects but ultimately compromise neuronal function and cause cell death. The current review, assembled by participants of the Chiclana Summer School on Neuroinflammation 2016, provides an overview of our current understanding of AD-related immune processes. We describe the principal cellular and molecular players in inflammation as they pertain to AD, examine modifying factors, and discuss potential future therapeutic targets.